You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 3.3% | 3.5% |
Div Cover | 0.0 | 2.2 |
Op Mrgn | 21.5% | 26.4% |
ROCE | 35.5% |
Latest | Forecast | |
---|---|---|
P/E | 2,058.4 | 1,291.3 |
PEG | -41.7 | 0.0 |
Price / Revenue | 3.4 | 3.0 |
Price / Book value | 1.9 |
Latest | Forecast | |
---|---|---|
Revenue | 4.8% | 6.5% |
PBT | -43.4% | n/a |
EPS | -49.3% | 9.3% |
DPS | 4.1% | 2.2% |
Year Ending | Revenue (€m) |
Pre-tax (€m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2017-12-31 | 35,055.00 | 5,634.00 | €3.02 | 23.8 | -2.0 | -12% | €3.03 | 4.2% |
2018-12-31 | 34,463.00 | 4,904.00 | €3.46 | 21.9 | 1.5 | 15% | €3.07 | 4.1% |
2019-12-31 | 36,126.00 | 3,077.00 | €2.33 | 38.5 | -1.2 | -33% | €3.15 | 3.5% |
2020-12-31 | 36,041.00 | 13,778.00 | €0.10 | 802.2 | -8.4 | -96% | €3.20 | 4.1% |
2021-12-31 | 37,761.00 | 7,798.00 | €0.05 | 1,782.3 | -36.1 | -49% | €3.33 | 3.8% |
GSK and Sanofi seek approval for Covid-19 jab Sharecast News | 23 Feb |
---|---|
GSK-Sanofi Covid jab shows 'strong' immune response Sharecast News | 15 Dec |
Sanofi to buy biopharmaceutical group Kadmon in $1.9bn deal Sharecast News | 08 Sep |